Latest news with #SpringWorksTherapeutics
Yahoo
27-05-2025
- Business
- Yahoo
SpringWorks Therapeutics (SWTX) Surged on Acquisition News
Carillon Tower Advisers, an investment management company, released its 'Carillon Eagle Small Cap Growth Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop in Q1, with the Russell 2000 Growth Index (down 11.12%) trailing the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate, which increased by 1.76%, outperformed all sectors both absolutely and relatively. The only other sector delivering positive returns was consumer staples, which rose by 0.67%. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as SpringWorks Therapeutics, Inc. (NASDAQ:SWTX). Headquartered in Stamford, Connecticut, SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a biopharmaceutical company. The one-month return of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) was 0.65%, and its shares gained 9.67% of their value over the last 52 weeks. On May 23, 2025, SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) stock closed at $46.48 per share with a market capitalization of $3.5 billion. Carillon Eagle Small Cap Growth Fund stated the following regarding SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in its Q1 2025 investor letter: "SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a commercial-stage biopharmaceutical company that develops treatments for various diseases and cancers. During the first quarter, a major pharmaceutical company announced that it was in talks to acquire SpringWorks. In response, SpringWorks cancelled all meetings and its earnings call, reflecting the significance of the potential deal. Although no agreement has been finalized, the stock performed well last quarter." A closeup of a scientist in a lab coat, mixing two liquids for a compound to treat rare diseases. SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 71 hedge fund portfolios held SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) and shared the list of best immunology stocks to buy. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Recorder
15-05-2025
- Business
- Business Recorder
Merck KGaA strikes more cautious tone on 2025 profit
FRANKFURT: German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing the macro-economic and geopolitical environment as well as foreign-exchange headwinds. Earnings before interest, tax, depreciation and amortization (EBITDA), adjusted for one-off items, would likely reach between 5.8 billion euros ($6.5 billion) and 6.4 billion this year, compared with 6.07 billion euros reported for 2024. It had previously issued a target range of between 6.1 billion euros and 6.6 billion. 'The slight adjustment to the guidance in Life Science, Merck's biggest business sector, is also related to the current uncertainties around tariffs,' the company said in a statement, referring to a division that makes biotech lab equipment and supplies. First-quarter adjusted EBITDA gained 5.6% to 1.54 billion euros, the group said, slightly ahead of an analyst consensus of 1.51 billion posted on the company's website. Merck last month struck a deal to buy U.S. biotech company SpringWorks Therapeutics for $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring drug patents. On Wednesday, it dropped a surcharge on orders of lab equipment and substances within China following the U.S.-China agreement to pause sky-high tariffs on each other.
Yahoo
30-04-2025
- Business
- Yahoo
Merck KGaA to Buy Springworks for $3.9B
German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer and rare diseases and is expected to give a boost to Merck's health-care division. Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal. Sign in to access your portfolio
Business Insider
29-04-2025
- Business
- Business Insider
SpringWorks Therapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded SpringWorks Therapeutics (SWTX) to Hold from Buy with a price target of $47, down from $66, after the company and Merck KGaA (MKKGY) announced a definitive agreement for Merck KGaA to acquire SpringWorks for $47 per share in cash. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Bloomberg
28-04-2025
- Business
- Bloomberg
Merck KGaA to Buy Springworks for $3.9B
German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer and rare diseases and is expected to give a boost to Merck's health-care division. Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal. (Source: Bloomberg)
